Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...

An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...